Maxele Advisors LLC Makes New Investment in iShares Biotechnology ETF $IBB

Maxele Advisors LLC purchased a new position in shares of iShares Biotechnology ETF (NASDAQ:IBB) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 4,670 shares of the financial services provider’s stock, valued at approximately $674,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Brighton Jones LLC bought a new position in iShares Biotechnology ETF in the 4th quarter worth $201,000. AQR Capital Management LLC purchased a new stake in iShares Biotechnology ETF in the first quarter worth about $455,000. Millennium Management LLC raised its stake in shares of iShares Biotechnology ETF by 140.8% in the first quarter. Millennium Management LLC now owns 41,676 shares of the financial services provider’s stock worth $5,330,000 after buying an additional 143,893 shares during the period. Vise Technologies Inc. purchased a new position in shares of iShares Biotechnology ETF during the 2nd quarter valued at about $348,000. Finally, Banco Bilbao Vizcaya Argentaria S.A. bought a new position in shares of iShares Biotechnology ETF during the 2nd quarter valued at approximately $588,000. 62.45% of the stock is currently owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Price Performance

iShares Biotechnology ETF stock opened at $167.14 on Tuesday. The firm has a 50 day moving average of $172.68 and a 200 day moving average of $162.92. iShares Biotechnology ETF has a 12-month low of $107.43 and a 12-month high of $179.64.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.